Preventing the spread of HIV: The PopART study

GERF Case study - HIV prevention (readable format)

Key people and organisations

• HIV Preventions Trial Network
• School of Hygeine and Tropical Medicine
• Zambart (Zambia)
• Desmond Tutu TB Centre (South Africa)
• Oxford University
• Professor Sarah Fidler

Publications and news

• Thomas et al. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial. The Lancet Global Health (2021); 9(5): E6680E680. 
• Universal ‘Test and Treat’ for HIV cost-effective in high prevalence regions
• ‘Test and Treat’ reduces new HIV infections by a third in African communities

Funding

• National Institute of Allergy and Infectious Diseases (NIAID) under the cooperative agreements UM1-AI068619, UM1-AI068617, and UM1-AI068613, with funding from PEPFAR; the 3ie with support from the Bill & Melinda Gates Foundation; and by NIAID, the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), all of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, NIMH, NIDA, PEPFAR, 3ie, or the Bill & Melinda Gates Foundation. KH, MP, and AC acknowledge the MRC Centre for Global Infectious Disease Analysis ( reference MR/R015600/1 ), jointly funded by the MRC and the UK Department for International Development (DFID), under the MRC-DFID concordat agreement and also part of the European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) programme supported by the EU. KH also acknowledges the Abdul Latif Jameel Institute for Disease and Emergency Analytics, funded by the Abdul Latif Jameel Foundation. KH and AC acknowledge the NIHR HPRU in Modelling and Health Economics, a partnership between Public Health England, Imperial College London, and the London School of Hygiene & Tropical Medicine ( grant number NIHR200908 ). RJH and SFl acknowledge the MRC and DFID (reference MR/R010161/1) under the MRC-DFID concordat agreement, also part of the EDCTP2 programme supported by the EU. SFi receives funding support from the NIHR Imperial Biomedical Research Centre.